welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of the company’s pivotal Phase 3 trial, CPP FAP-310, evaluating CPP-1X/sulindac for adults with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. For most FAP patients, current medical practice recommends a lifetime of periodic monitoring as well as surgeries (FAP-related events). These FAP-related events include surgical removal of the colon, rectum, surgical pouch, duodenum, and/or high risk adenomas.
expertly curated content related to this topic
-
Clinical Management of Adenomatous Polyposis in Patients with Hereditary Non-Polyposis Colorectal Cancer and Familia...OBJECTIVE : To investigate the validity ...
-
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner SyndromeThe purpose of this study is to assess t...
-
Frank A. Sinicrope, MDInterests: Colorectal cancer prevention...
-
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Pati...This is a registry-based observation...
-
Op-Ed: Obama’s ‘Precision Medicine Initiative’ is a Moon Worth Shooting ForMary Beckerle, Ph.D., CEO of the Huntsma...
-
Chemoprevention of Colorectal CancerColorectal cancer has become one of the ...
-
Desmoid Tumors do not Prevent Proctectomy following Abdominal Colectomy and Ileorectal Anastomosis in Patients with ...BACKGROUND: Elective proctocolectomy ha...